Monday, July 15, 2024

Corteva cuts full-year sales forecasts but analysts say ‘better than feared’

Must read

Tractor spraying wheat field, aerial view

Bim/E+ via Getty Images

Corteva (NYSE:CTVA) +1.1% in Friday’s trading despite cutting full-year guidance, with analysts saying the weaker outlook is “better than feared.”

Q2 adjusted earnings came in better than expected at $1.60/share compared with the $1.58/share analyst consensus estimate, but net sales fell 3% Y/Y to $6.05B, below expectations; the company’s seed business rose 8% Y/Y to $4.26B off a 14% rise in prices, while crop chemical sales fell 23%.

But citing delayed farmer purchases this year and an industry-wide destocking of farm products, Corteva (CTVA) cut full-year guidance for sales to $17.9B-$18.2B from its prior outlook for $18.6B-$18.9B previously, operating earnings to $2.75-$2.90/share from $2.80-$3.00/share previously, and adjusted EBITDA to $3.5B-$3.65 from $3.55B-$3.75B.

At least two analysts – Wells Fargo’s Richard Garchitorena and Oppenheimer’s Kristen Owen – called the downward revisions “better than feared.”

Corteva (CTVA) said higher interest rates and improved product available after supply chain issues a year ago has led to a pullback in buying, and farmers have switched to more just-in-time buying for their pesticides.

Agriculture peer FMC Corp. (FMC), which had cut its full-year outlook in July, said this week it expects the global crop protection market will decline by high single to low double digits during the year.

More on Corteva:

More articles

Latest article